CD274 and neoplasm: Jing et al. investigated potential predictors of irAE risk in patients receiving anti-PD-1/PD-L1 therapy for 26 different tumor types by integrating real-world pharmacoalertness and molecular omics data and showed that a bivariate linear-regression model based on lymphocyte cystolic protein 1 and adenosine diphosphate-dependent glucokinase expression could accurately predict irAEs [50].